IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+35.4%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$328M
AUM Growth
+$328M
(+46%)
Cap. Flow
+$56M
Cap. Flow
% of AUM
17.07%
Top 10 Holdings %
Top 10 Hldgs %
34.61%
Holding
78
New
27
Increased
13
Reduced
13
Closed
18
Top Buys
| 1 |
LHCG
LHC Group LLC
LHCG
|
$13.1M |
| 2 |
Charles River Laboratories
CRL
|
$9.59M |
| 3 |
Cencora
COR
|
$9.07M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$7.65M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$7.48M |
Top Sells
| 1 |
Medtronic
MDT
|
$10.4M |
| 2 |
Centene
CNC
|
$10.1M |
| 3 |
Encompass Health
EHC
|
$7.36M |
| 4 |
Masimo
MASI
|
$6.2M |
| 5 |
Novartis
NVS
|
$5.77M |
Sector Composition
| 1 | Healthcare | 88.41% |
| 2 | Energy | 6.64% |
| 3 | Technology | 0.85% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Merck
MRK
$210B
| $5.8M | 1.74% | 75,000 -55,000 | -42% | -$4.25M |
|
27
Eli Lilly
LLY
$657B
| $5.75M | 1.72% | +35,000 | New | +$5.75M |
|
|
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.71M | 1.71% | 50,000 +10,000 | +25% | +$1.14M |
|
|
MNTA
29
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $4.99M | 1.49% | +150,000 | New | +$4.99M |
|
30
Exact Sciences
EXAS
$8.98B
| $4.78M | 1.43% | 55,000 -25,000 | -31% | -$2.17M |
|
31
Abbott
ABT
$231B
| $4.57M | 1.37% | 50,000 +5,000 | +11% | +$457K |
|
|
HZNP
32
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.45M | 1.33% | +80,000 | New | +$4.45M |
|
33
Baxter International
BAX
$12.7B
| $4.31M | 1.29% | +50,000 | New | +$4.31M |
|
34
Zimmer Biomet
ZBH
$21B
| $4.18M | 1.25% | +35,000 | New | +$4.18M |
|
35
McKesson
MCK
$85.4B
| $3.84M | 1.15% | 25,000 | – | – |
|
36
Envista
NVST
$3.52B
| $3.69M | 1.11% | +175,000 | New | +$3.69M |
|
37
Halozyme
HALO
$8.56B
| $3.62M | 1.08% | 135,000 +85,000 | +170% | +$2.28M |
|
38
Exelixis
EXEL
$10.1B
| $3.56M | 1.07% | 150,000 | – | – |
|
39
Gossamer Bio
GOSS
$562M
| $3.51M | 1.05% | +270,000 | New | +$3.51M |
|
40
Insulet
PODD
$23.9B
| $3.5M | 1.05% | +18,000 | New | +$3.5M |
|
41
Akebia Therapeutics
AKBA
$833M
| $3.4M | 1.02% | 250,000 +50,000 | +25% | +$679K |
|
42
Denali Therapeutics
DNLI
$2.23B
| $3.14M | 0.94% | 130,000 +40,000 | +44% | +$967K |
|
43
Revvity
RVTY
$10.5B
| $2.94M | 0.88% | 30,000 -15,000 | -33% | -$1.47M |
|
|
CHNG
44
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $2.8M | 0.84% | +250,000 | New | +$2.8M |
|
|
DRNA
45
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $2.79M | 0.84% | 110,000 -75,000 | -41% | -$1.91M |
|
46
AbbVie
ABBV
$372B
| $2.46M | 0.74% | +25,000 | New | +$2.46M |
|
47
Neurocrine Biosciences
NBIX
$13.8B
| $2.44M | 0.73% | +20,000 | New | +$2.44M |
|
|
ZGNX
48
DELISTED
Zogenix, Inc.
ZGNX
| $2.43M | 0.73% | +90,000 | New | +$2.43M |
|
|
AMRN
49
Amarin Corp
AMRN
$311M
| $2.42M | 0.73% | +350,000 | New | +$2.42M |
|
50
Fate Therapeutics
FATE
$120M
| $2.4M | 0.72% | 70,000 -25,000 | -26% | -$858K |
|